Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 22, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 375,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,332.153 pence per share.
- Treasury Shares Held: 106,623,000 shares (post-transaction).
- Shares in Issue: 5,837,624,117 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 375,000 shares on August 22, 2005. These shares were added to the company's Treasury holdings. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying the 375,000 shares by the price of 1,332.153 pence.
- Confirm the updated total share count (5,837,624,117 issued) against subsequent filings to track dilution or further buybacks.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authority granted.
- Note that this filing is a transactional report and does not replace quarterly or annual financial results.